BioXcel Therapeutics Q3 revenue misses analyst expectations

BioXcel Therapeutics

12/11/2025 12:09

Overview

BioXcel Q3 2025 revenue and net income miss analyst expectations

Company plans sNDA submission for BXCL501 in Q1 2026

BioXcel advances late-stage clinical trials for BXCL501

Outlook

BioXcel plans to submit an sNDA for IGALMI® in Q1 2026

Company preparing for TRANQUILITY In-Care Phase 3 Trial

BioXcel sees U.S. at-home agitation market at 57-77 mln episodes annually

Result Drivers

R&D EXPENSES - Increased due to heightened clinical trial activity, particularly related to the SERENITY at-home Phase 3 studies

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$98,000
$216,000 (5 Analysts)
Q3 Net Income
Miss
-$30.91 mln
-$14.10 mln (5 Analysts)
Q3 Basic EPS
Miss
-$2.18
-$1.24 (5 Analysts)
Q3 Operating Income
Miss
-$14.23 mln
-$11.40 mln (4 Analysts)
Q3 Operating Expenses
$14.33 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for BioXcel Therapeutics Inc is $12.00, about 83.2% above its November 11 closing price of $2.02

Press Release: ID:nGNX9M37cN

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)